Here's an excerpt from Diedtra Henderson's Boston Globe story on the successful treatments devised by Osiris Therapeutics using adult stem cells...
As Congress spent hours passionately debating the merits and ethics of embryonic stem cell research, nearly 50 Osiris Therapeutics Inc. employees here continued their quiet work on less controversial adult stem cells.
Thanks to Food and Drug Administration fast-track designation, Osiris expects to have an adult stem cell-based therapy on the market by late 2007 to combat potentially fatal tissue rejection among leukemia patients undergoing bone marrow transplants.
That's one of three adult stem cell-based therapies Osiris currently has in human trials, to the delight of investors who muscled their way into the company's latest funding round to raise $50 million, more than double the expected amount.
